On July 16, the National Health Insurance Administration issued the “2025 National Statistical Bulletin on the Development of Medical Insurance Services”. According to the communiqué, the “National Catalogue of Drugs for Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance” includes a total of 3,253 types of Western medicines and proprietary Chinese medicines, including 1,857 types of Western medicines and 1,396 types of proprietary Chinese medicines. In 2025, 114 new drugs will be added. Since the establishment of the National Health Insurance Administration in 2018, the medical insurance drug catalogue has been adjusted every year, and a total of 949 new drugs have been added to the catalogue. During the 2025 agreement period, 248 million drug reimbursements were negotiated. In 2025, the “Catalogue of Innovative Drugs for Commercial Health Insurance” was added, focusing on innovative drugs with a high degree of innovation, high clinical value, significant patient benefits, and beyond the scope of basic medical insurance coverage. The first edition of the catalogue included a total of 19 drugs.

On July 16, the National Health Insurance Administration issued the “2025 National Statistical Bulletin on the Development of Medical Insurance Services”. According to the communiqué, the “National Catalogue of Drugs for Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance” includes a total of 3,253 types of Western medicines and proprietary Chinese medicines, including 1,857 types of Western medicines and 1,396 types of proprietary Chinese medicines. In 2025, 114 new drugs will be added. Since the establishment of the National Health Insurance Administration in 2018, the medical insurance drug catalogue has been adjusted every year, and a total of 949 new drugs have been added to the catalogue. During the 2025 agreement period, 248 million drug reimbursements were negotiated. In 2025, the “Catalogue of Innovative Drugs for Commercial Health Insurance” was added, focusing on innovative drugs with a high degree of innovation, high clinical value, significant patient benefits, and beyond the scope of basic medical insurance coverage. The first edition of the catalogue included a total of 19 drugs.